Delivery Order SPE2DB24D3013-SPE2DB25FFPSV
- Not listed
- The Defense Logistics Agency awarded a $7,575.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Imbruvica 420 mg tablets (28-count units). This non-set-aside contract is scheduled for completion by September 10, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 9, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Imbruvica 140mg (90-count units) with a ceiling value of $16,233.76 under a firm fixed-price contract type. The contract has an ultimate completion date of September 2, 2025, and was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with the place...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count units) valued at $53,030.25 with a firm fixed price structure. The order is scheduled for completion by September 9, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract and is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Imbruvica 70 mg capsules (28-count units) with a contract value of $7,575.75. This is a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The award was made through open competition with no set-aside designation, and the place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $22,727.25 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count packaging) under a firm fixed price contract type. The delivery order, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, carries no set-aside designation, indicating it was awarded through open competition. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $37,878.75 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) on August 14, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $15,151.52 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) under a firm fixed price contract. This non-competitive set-aside delivery order is scheduled for completion by September 2, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of pharmaceutical supply services through AmerisourceBergen's extensive federal...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $15,151.52 on July 24, 2025, for the supply of Imbruvica 280 mg tablets (28-count packaging) to support federal medical procurement needs. The contract carries a firm fixed price structure and is not set aside for any particular business category. Performance is scheduled for completion by August 14, 2025, with work being conducted at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of IMBRUVICA 140 mg capsules (90-count units) with a ceiling value of $16,233.74. This competitively awarded, firm fixed-price contract has an ultimate completion date of September 10, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFPSVDelivery Order
The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Imbruvica 140 mg tablets (28-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by September 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates consistent capability in fulfilling DLA medical procurement requirements across multiple therapeutic domains, positioning the company as a critical vendor for defense health system pharmaceutical needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 8/22/25 |